Real-World Experience With Secukinumab for Hidradenitis Suppurativa: A Multicenter Retrospective Analysis of 263 Patients From the SECU-SPAIN Study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Martorell A, Vilarrasa-Rull E, Fernandez-Crehuet P, Molina-Leyva A, Mansila-Polo M, Garcia-Ruiz R, Garbayo-Salmons P, Ortiz-Salvador J M, Alfageme-Roldan F, Garcias-Ladaria J, Bassas-Vila J, Fuertes-de-Vega I, Carnero-Gonzalez L, Almenara-Blasco M, Torres-Navarro I, Aguayo-Ortiz R, Gil Pallares P, Fornons-Servent R, Gracia-Darder I, Mora-Fernández V, Corral O, Pericet-Fernandez L, Navarro F, Haselgruber S, Ochando-Ibernon G, Menéndez-Parron A, Masferrer E, Gamissans M, Solera-Talamante M, Moya M, Imbernon A, Melgosa J, Spanish Hidradenitis Suppurativa Group (GEHS)
Аннотация
METHODS: This retrospective, multicenter study included patients with moderate-to-severe HS treated with secukinumab (300mg every four weeks) between 2020 and 2024. Eligible patients were aged ≥18 years, with a clinical diagnosis of moderate-to-severe HS, and a minimum follow-up of 24 weeks. Key exclusions included patients treated with nonstandard secukinumab dosing regimens or those with insufficient clinical data. The primary endpoints were achievement of HiSCR50 (≥50% reduction in the combined count of nodules and abscesses) at weeks 16 and 24). Secondary endpoints included achieving a ≥55% reduction in the International HS Severity Score (IHS4-55) and adverse events.
RESULTS: A total of 263 patients (49.4%, women; 50.6%, men; mean age, 41.8±13.2 years) were included. The most common HS phenotype was mixed (49.4%), and 55.1% had Hurley stage III disease. At weeks 16 and 24, a total of 57.4% and 63.6% of patients achieved HiSCR50, respectively. The mean IHS4 score dropped significantly from 16.7±10.0 at baseline to 7.6±5.6 at week 24 (p<0.0001). At weeks 16 and 24, 52% and 56% of patients achieved an IHS4-55 response. Secukinumab was discontinued in 14.5% of patients because of lack of efficacy or adverse events.
CONCLUSIONS: Secukinumab demonstrated a significant safety and efficacy profile for patients with moderate-to-severe in a real-world setting, with better outcomes than those reported in earlier clinical trials. Response evaluation at both week 16 and 24 is crucial due to variations in treatment effectiveness.